Tscan Therapeutics Inc (NASDAQ: TCRX) kicked off on Monday, down -10.92% from the previous trading day, before settling in for the closing price of $1.74. Over the past 52 weeks, TCRX has traded in a range of $1.71-$9.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 167.40%. While this was happening, its average annual earnings per share was recorded -14.36%. With a float of $43.27 million, this company’s outstanding shares have now reached $52.31 million.
Considering the fact that the conglomerate employs 194 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 15.84%, operating margin of -4787.68%, and the pretax margin is -4527.66%.
Tscan Therapeutics Inc (TCRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Tscan Therapeutics Inc is 23.53%, while institutional ownership is 69.42%. The most recent insider transaction that took place on Dec 13 ’24, was worth 290,140. In this transaction 10% Owner of this company bought 100,000 shares at a rate of $2.90, taking the stock ownership to the 5,357,347 shares. Before that another transaction happened on Dec 12 ’24, when Company’s 10% Owner bought 31,800 for $3.01, making the entire transaction worth $95,629. This insider now owns 5,257,347 shares in total.
Tscan Therapeutics Inc (TCRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.58% during the next five years compared to -14.41% drop over the previous five years of trading.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Take a look at Tscan Therapeutics Inc’s (TCRX) current performance indicators. Last quarter, stock had a quick ratio of 8.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 31.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.06, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.25 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
Compared to the last year’s volume of 0.36 million, its volume of 0.43 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 11.24%. Additionally, its Average True Range was 0.18.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 0.85%, which indicates a significant decrease from 6.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.37% in the past 14 days, which was higher than the 85.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.2904, while its 200-day Moving Average is $4.8062. Nevertheless, the first resistance level for the watch stands at $1.6900 in the near term. At $1.8300, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.9200. If the price goes on to break the first support level at $1.4600, it is likely to go to the next support level at $1.3700. Now, if the price goes above the second support level, the third support stands at $1.2300.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
The company with the Market Capitalisation of 87.72 million has total of 56,591K Shares Outstanding. Its annual sales at the moment are 2,820 K in contrast with the sum of -127,500 K annual income. Company’s last quarter sales were recorded 670 K and last quarter income was -35,810 K.
